title: Effect of buthionine sulphoximine, glutathione and methimazole on the renal disposition of cisplatin and on cisplatin-induced nephrotoxicity in rats: pharmacokinetic-toxicodynamic analysis.
abstract: The aim of this study was to classify the protective mechanisms of DL-buthionine-(S,-R)-sulphoximine, glutathione and methimazole on cisplatin-induced nephrotoxicity in rats. An Emax model was used to study the effect of these compounds on the pharmacokinetics of cisplatin, especially renal handling and intra-renal biotransformation. Cisplatin (5 mg kg(-1)) was administered as an intravenous bolus to rats treated with either 0.9% NaCl (control), buthionine sulphoximine, glutathione or methimazole. The blood urea nitrogen level was monitored to estimate cisplatin-induced nephrotoxicity. To estimate renal handling of cisplatin, cisplatin was infused intravenously to rats treated with 0.9% NaCl, buthionine sulphoximine, glutathione or methimazole. The concentrations of unchanged cisplatin in plasma, urine and kidney were determined by a post-column derivatization HPLC method. The relationship between the pharmacokinetics and toxicodynamics of cisplatin was analysed using a sigmoid Emax model. All compounds studied ameliorated significantly the nephrotoxicity of cisplatin. The renal accumulation of cisplatin was reduced significantly by pretreatment with buthionine sulphoximine but not by either glutathione or methimazole. Although glutathione treatment did not affect the renal accumulation of cisplatin, it significantly decreased the binding of cisplatin to the intrarenal organelle and the decreased binding was well correlated to the decrease of the blood urea nitrogen level. In summary, pharmacokinetic-toxicodynamic analysis will be useful for classifying the protective mechanism of cisplatin-induced nephrotoxicity.
authors.affiliation: Department of Biopharmaceutics, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Hanada
authors.forename: Y
authors.initials: Y
authors.lastname: Mukasa
authors.forename: Y
authors.initials: Y
authors.lastname: Nomizo
authors.forename: H
authors.initials: H
authors.lastname: Ogata
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics; D019540:Area Under Curve; D001806:Blood Urea Nitrogen; D019328:Buthionine Sulfoximine / Q000494:pharmacology*; D002945:Cisplatin / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D005978:Glutathione / Q000494:pharmacology*; D066298:In Vitro Techniques; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D007672:Kidney Cortex / Q000187:drug effects / Q000378:metabolism; D007674:Kidney Diseases / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D008297:Male; D008713:Methimazole / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013696:Temperature; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D019328:Buthionine Sulfoximine; D008713:Methimazole; D005978:Glutathione; D002945:Cisplatin